The Resource Treatments for schizophrenia in adults : a systematic review, prepared for Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services ; prepared by Pacific Northwest Evidence-based Practice Center ; investigators, Marian S. McDonagh, Tracy Dana, Shelley Selph, Emily B. Devine, Amy Cantor, Christina Bougatsos, Ian Blazina, Sara Grusing, Rochelle Fu, Sarah L. Kopelovich, Maria Monroe-DeVita, Daniel W. Haupt

Treatments for schizophrenia in adults : a systematic review, prepared for Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services ; prepared by Pacific Northwest Evidence-based Practice Center ; investigators, Marian S. McDonagh, Tracy Dana, Shelley Selph, Emily B. Devine, Amy Cantor, Christina Bougatsos, Ian Blazina, Sara Grusing, Rochelle Fu, Sarah L. Kopelovich, Maria Monroe-DeVita, Daniel W. Haupt

Label
Treatments for schizophrenia in adults : a systematic review
Title
Treatments for schizophrenia in adults
Title remainder
a systematic review
Statement of responsibility
prepared for Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services ; prepared by Pacific Northwest Evidence-based Practice Center ; investigators, Marian S. McDonagh, Tracy Dana, Shelley Selph, Emily B. Devine, Amy Cantor, Christina Bougatsos, Ian Blazina, Sara Grusing, Rochelle Fu, Sarah L. Kopelovich, Maria Monroe-DeVita, Daniel W. Haupt
Creator
Contributor
Author
Issuing body
Sponsoring body
Subject
Genre
Language
eng
Summary
OBJECTIVES: This systematic review (SR) provides evidence on pharmacological and psychosocial treatments for schizophrenia. DATA SOURCES: MEDLINE(r), the Cochrane Library databases, PsycINFO(r), and included studies through February 2017. STUDY SELECTION: We included studies comparing second-generation antipsychotics (SGA) with each other or with a first-generation antipsychotic (FGA) and studies comparing psychosocial interventions with usual care in adults with schizophrenia. DATA EXTRACTION: We extracted study design, year, setting, country, sample size, eligibility criteria, population, clinical and intervention characteristics, results, and funding source. RESULTS: We included 1 SR of 138 trials (N=47,189) and 24 trials (N=6,672) for SGAs versus SGAs, 1 SR of 111 trials (N=118,503) and 5 trials (N=1,055) for FGAs versus SGAs, and 13 SRs of 271 trials (N=25,050) and 27 trials (n=6,404) for psychosocial interventions. Trials were mostly fair quality and strength of evidence was low or moderate. For drug therapy, the majority of the head-to-head evidence was on older SGAs, with sparse data on SGAs approved in the last 10 years (asenapine, lurasidone, iloperidone, cariprazine, brexpiprazole) and recent long-acting injection (LAI) formulations of aripiprazole and paliperidone. Older SGAs were similar in measures of function, quality of life, mortality, and overall adverse events, except that risperidone LAI had better social function than quetiapine. Core illness symptoms were improved more with olanzapine and risperidone than asenapine, quetiapine, and ziprasidone, and more with paliperidone than lurasidone and iloperidone; all were superior to placebo. Risperidone LAI and olanzapine had less withdrawal due to adverse events. Compared with olanzapine and risperidone, haloperidol, the most studied FGA, had similar improvement in core illness symptoms, negative symptoms, symptom response, and remission but greater incidence of adverse event outcomes. In comparison with usual care, most psychosocial interventions reviewed were more effective in improving intervention-targeted outcomes, including core illness symptoms. Various functional outcomes were improved more with assertive community treatment, cognitive behavioral therapy, family interventions, psychoeducation, social skills training, supported employment, and early interventions for first episode psychosis (FEP) than with usual care. Quality of life was improved more with cognitive behavioral therapy and early interventions for FEP than usual care. Relapse was reduced with family interventions, psychoeducation, illness self-management, family interventions, and early interventions for FEP. CONCLUSIONS: Most comparative evidence on pharmacotherapy relates to the older drugs, with clozapine, olanzapine, and risperidone superior on more outcomes than other SGAs. Older SGAs were similar to haloperidol on benefit outcomes but had fewer adverse event outcomes. Most psychosocial interventions improved functional outcomes, quality of life, and core illness symptoms, and several reduced relapse compared with usual care
Member of
Cataloging source
NLM
http://library.link/vocab/creatorName
McDonagh, Marian S
Government publication
federal national government publication
Illustrations
illustrations
Index
no index present
Literary form
non fiction
Nature of contents
  • dictionaries
  • surveys of literature
NLM call number
WM 203
http://library.link/vocab/relatedWorkOrContributorName
  • Oregon Health & Science University
  • United States
Series statement
  • AHRQ publication
  • Comparative effectiveness review
Series volume
  • no. 17(18)-EHC031-EF
  • number 198
http://library.link/vocab/subjectName
  • Schizophrenia
  • Antipsychotic Agents
  • Outcome Assessment, Health Care
Label
Treatments for schizophrenia in adults : a systematic review, prepared for Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services ; prepared by Pacific Northwest Evidence-based Practice Center ; investigators, Marian S. McDonagh, Tracy Dana, Shelley Selph, Emily B. Devine, Amy Cantor, Christina Bougatsos, Ian Blazina, Sara Grusing, Rochelle Fu, Sarah L. Kopelovich, Maria Monroe-DeVita, Daniel W. Haupt
Instantiates
Publication
Note
"October 2017."
Bibliography note
Includes bibliographical references
Carrier category
online resource
Carrier category code
  • cr
Carrier MARC source
rdacarrier
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Control code
1039284830
Extent
1 online resource (various paginges)
Form of item
online
Media category
computer
Media MARC source
rdamedia
Media type code
  • c
Other physical details
illustrations.
Specific material designation
remote
System control number
(OCoLC)1039284830
Label
Treatments for schizophrenia in adults : a systematic review, prepared for Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services ; prepared by Pacific Northwest Evidence-based Practice Center ; investigators, Marian S. McDonagh, Tracy Dana, Shelley Selph, Emily B. Devine, Amy Cantor, Christina Bougatsos, Ian Blazina, Sara Grusing, Rochelle Fu, Sarah L. Kopelovich, Maria Monroe-DeVita, Daniel W. Haupt
Publication
Note
"October 2017."
Bibliography note
Includes bibliographical references
Carrier category
online resource
Carrier category code
  • cr
Carrier MARC source
rdacarrier
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Control code
1039284830
Extent
1 online resource (various paginges)
Form of item
online
Media category
computer
Media MARC source
rdamedia
Media type code
  • c
Other physical details
illustrations.
Specific material designation
remote
System control number
(OCoLC)1039284830

Library Locations

  • Health Sciences LibraryBorrow it
    2411 Holmes St, Kansas City, Kansas City, MO, 64108, US
    39.083418 -94.575323
  • LaBudde Special CollectionsBorrow it
    800 E 51st St, Kansas City, MO, 64110, US
    39.034642 -94.576835
  • Leon E. Bloch Law LibraryBorrow it
    500 E. 52nd Street, Kansas City, MO, 64110, US
    39.032488 -94.581967
  • Marr Sound ArchivesBorrow it
    800 E 51st St, Kansas City, MO, 64110, US
    39.034642 -94.576835
  • Miller Nichols LibraryBorrow it
    800 E 51st St, Kansas City, MO, 64110, US
    39.035061 -94.576518
  • UMKCBorrow it
    800 E 51st St, Kansas City, MO, 64110, US
    39.035061 -94.576518
  • UMKCBorrow it
    800 E 51st St, Kansas City, MO, 64110, US
Processing Feedback ...